Intra-Cellular Therapies ...
126.84
-0.35 (-0.28%)
At close: Jan 14, 2025, 3:59 PM
126.73
-0.09%
After-hours Jan 14, 2025, 06:20 PM EST
undefined%
Bid 126.71
Market Cap 13.45B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.86
PE Ratio (ttm) -147.49
Forward PE n/a
Analyst Buy
Ask 126.97
Volume 15,775,357
Avg. Volume (20D) 1,202,206
Open 127.20
Previous Close 127.19
Day's Range 126.84 - 127.45
52-Week Range 62.78 - 128.00
Beta undefined

About ITCI

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as ...

Sector Healthcare
IPO Date Jan 7, 2014
Employees 610
Stock Exchange NASDAQ
Ticker Symbol ITCI

Analyst Forecast

According to 13 analyst ratings, the average rating for ITCI stock is "Buy." The 12-month stock price forecast is $100, which is a decrease of -21.16% from the latest price.

Buy 69.23%
Hold 30.77%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Intra-Cellular Therapies Inc. is scheduled to release its earnings on Feb 20, 2025, before market opens.
Analysts project revenue of $193.96M, reflecting a 46.83% YoY growth and earnings per share of -0.11, making a -63.33% decrease YoY.
2 days ago · Source
+34.07%
Intra-Cellular Therapies shares are trading higher... Unlock content with Pro Subscription
2 months ago · Source
+11.36%
Intra-Cellular Therapies shares are trading higher after the company reported better-than-expected Q3 revenue results and raised its FY24 net product sales guidance. Also, Needham reiterated a Buy rating on the stock.